1. Home
  2. ABLV vs FEMY Comparison

ABLV vs FEMY Comparison

Compare ABLV & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.74

Market Cap

39.5M

Sector

N/A

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.58

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
FEMY
Founded
2015
2004
Country
China
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
37.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ABLV
FEMY
Price
$0.74
$0.58
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.83
AVG Volume (30 Days)
19.6K
1.2M
Earning Date
09-30-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$114,319,869.00
$2,061,502.00
Revenue This Year
N/A
$64.02
Revenue Next Year
N/A
$147.19
P/E Ratio
$15.66
N/A
Revenue Growth
N/A
63.53
52 Week Low
$0.59
$0.31
52 Week High
$1.77
$1.80

Technical Indicators

Market Signals
Indicator
ABLV
FEMY
Relative Strength Index (RSI) 56.53 39.88
Support Level $0.65 $0.60
Resistance Level $0.77 $0.73
Average True Range (ATR) 0.07 0.05
MACD 0.01 0.00
Stochastic Oscillator 64.29 10.56

Price Performance

Historical Comparison
ABLV
FEMY

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: